Key result
Concurrent linezolid and SSRI use linked to serotonin syndrome and myelosuppression in two transplant cases.
Why the study?
The risks of serotonin syndrome and myelosuppression with concurrent use of linezolid and SSRIs in bone marrow transplant recipients are concerning and require clarification.
Case Report (n=2)
Concurrent use of linezolid and SSRIs should be avoided in bone marrow transplant recipients due to the risk of serotonin syndrome and myelosuppression.
Answers are grounded in this paper and cite their sources.
Suggests caution with linezolid and SSRIs in bone marrow transplant recipients; hypothesis-generating and requires prospective confirmation.
We report 2 cases of serotonin syndrome and myelosuppression in bone marrow transplant recipients who received linezolid in combination with a selective serotonin reuptake inhibitor (SSRI). Given the risks to patients in this high-risk group, we recommend that this combination of medications be avoided if alternative antibiotic therapy is possible. If no alternative therapy is possible, prescribers should discontinue SSRI therapy and monitor these patients closely for evidence of serotonin syndrome or the development of hematological toxicity.
No takes yet. Share an insight, caveat, or question.
Hachem et al. (2003) conducted a case report in Bone marrow transplant recipients (n=2). Concurrent use of linezolid and selective serotonin reuptake inhibitors (SSRIs) was evaluated on Serotonin syndrome and myelosuppression. Concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients was associated with serotonin syndrome and myelosuppression in two reported cases.
Synapse has enriched 10 related papers. Consider them for comparative context: